Pfizer announces a first-line combination Rx for advanced RCC.
On May 21st, 2019
NOW APPROVED
A new, first-line immunotherapy (IO) and tyrosine kinase inhibitor (TKI) combination for patients with advanced renal cell carcinoma (RCC)
Learn more ›
|
|||||||
No comments have been posted yet.